Brief: Theranexus Is Actively Pursuing Development Of Main Programmes

Thx Pharma SA

18/01/2021 17:42

Jan 18 (Reuters) - Theranexus SA  ALTHX.PA :
    * COMPANY IS ACTIVELY PURSUING THE DEVELOPMENT OF ITS MAIN
PROGRAMMES, WHICH ARE CURRENTLY FOCUSED MAINLY ON THN102 AND
BBDF-101.
    * AVAILABLE CASH AT 31 DECEMBER 2020 AMOUNTED TO EUR 11.2M
COMPARED WITH EUR 11.9M AT 30 SEPTEMBER 2020.
    * ON THN102 PROGRAM: THERANEXUS CONFIRMS ONGOING DISCUSSIONS
WITH
SEVERAL POTENTIAL PARTNERS, DEMONSTRATING THE PHARMACEUTICAL
INDUSTRY'S INTEREST IN THIS DRUG CANDIDATE
    * THN102 PROGRAM: VIEW TO SIGNING AGREEMENT BY END OF FIRST
HALF
OF 2021 WHICH WILL PAVE WAY FOR NEXT STAGES IN CLINICAL
DEVELOPMENT OF THN102 IN PARKINSON'S DISEASE.
    * BBDF-101 PROGRAM: DURING 4TH QUARTER OF 2020, RECEIVED
FAVORABLE
OPINION FROM U.S. FOOD AND DRUGS ADMINISTRATION(FDA) FOR
BBDF-101 PRECLINICAL DEVELOPMENT PLAN
    * BBDF-101 PROGRAM: NOW INTENDS TO OBTAIN FROM FDA AN
INVESTIGATIONAL NEW DRUG APPLICATION IN MID-2021 AND TO START
CLINICAL TRIAL BY END OF YEAR

Source text for Eikon:  ID:nACT67082 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))